- -

Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expresing Lymphoma Cells

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expresing Lymphoma Cells

Show full item record

De La Torre, C.; Casanova, I.; Acosta, G.; Coll Merino, MC.; Moreno, MJ.; Albericio, F.; Aznar, E.... (2015). Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expresing Lymphoma Cells. Advanced Functional Materials. 25(5):687-695. doi:10.1002/adfm.201403822

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/88406

Files in this item

Item Metadata

Title: Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expresing Lymphoma Cells
Author:
UPV Unit: Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials
Universitat Politècnica de València. Instituto de Reconocimiento Molecular y Desarrollo Tecnológico - Institut de Reconeixement Molecular i Desenvolupament Tecnològic
Issued date:
Abstract:
[EN] B-cell non-Hodgkin s lymphoma (B-NHL) is the most frequent malignant lymphoid neoplasm, which has a high degree of relapse and chemoresist-ance. Thus, strategies to improve currently used therapies are needed. In this ...[+]
Subjects: CXCR4 receptors , Gated materials , Lymphoma , Mesoporous materials , Targeting molecules
Copyrigths: Cerrado
Source:
Advanced Functional Materials. (issn: 1616-301X ) (eissn: 1616-3028 )
DOI: 10.1002/adfm.201403822
Publisher:
Wiley
Publisher version: http://dx.doi. org/10.1002/adfm.201403822
Thanks:
Financial support from the Spanish Government (MAT2012-38429-C04 and PIB2010BZ-00563), Generalitat Valenciana (PROMETEOII/2014/047), Generalitat de Catalunya (2009-SGR-1437), Instituto de Salud Carlos III (FI10/00758 and ...[+]
Type: Artículo

This item appears in the following Collection(s)

Show full item record